Petros Pharmaceuticals (PTPI) has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company’s recently announced SaaS-based technology, integrating Petros’ Software as a Medical Device proprietary solution, which is being designed to help facilitate expanding access for established prescription drugs by bringing them over the counter. The enhancements include: Addition of Deep Fake detection and mitigation features; Improved facial and ID recognition and matching capabilities; Enhanced image auto capture feature powered by machine learning technology.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTPI:
- AI Daily: Microsoft reports earnings, says Cloud, AI ‘essential inputs’
- Petros Pharmaceuticals developing SaaS Platform using AI, EHR
- Petros Pharmaceuticals trading halted, news pending
- Petros Pharmaceuticals to effect 1-for-25 reverse stock split
- Petros highlights Trump executive order on Rx-to-OTC reclassification reforms
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue